Keros Therapeutics Inc (NASDAQ:KROS) currently has a daily average trading volume of 1.37M but it saw 1732685 shares traded in last market. With a market cap of 486.90M USD, the company’s current market price of $12.02 came rising about 5.53 while comparing to the previous closing price of $11.39. In past 52 weeks, the stock remained buoying in the range of price level as high as $73.00 and as low as $9.77. In the recent trading on the day, stock has struck highest price mark of $11.22 while lowest mark touched by it was $12.075.
Taking a look at 20-day trading activity of Keros Therapeutics Inc (KROS) gives us an average price of $14.17, while its current price level is -83.53% below from 52-week high level whereas it is 22.97% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $36.31 while that of 200 days or SMA-200 reads an average of $48.69. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.46% during that period while stretching the period over a month that decreases to 6.23%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 25.15 which implies that the stock is in oversold territory.
Wedbush downgraded its recommendation for the stock as a “Neutral” from “Outperform” on January 17, 2025 while assigning a price target of $15. Oppenheimer issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $102 and $63.
Over the week, KROS’s stock price is moving 15.36% up while it is -28.96% when we observe its performance for the past one month. Year-to-date it is -24.07% down and over the past year, the stock is showing a downside performance of -78.06%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -0.43 while estimate for next year EPS is -4.12. In next quarter, company is expected to be making quarterly sales of $22.23M as analysts are expecting the sales for current fiscal year at $32.05M and seeing the company making $34.85M in sales next year. Moreover, analysts are in estimates of $37.32M for current-quarter revenue.
Currently, Keros Therapeutics Inc’s total number of outstanding shares is 39.26M with 2.05% of that held by the insiders while 100.48% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -33.00% and return on equity (ROE) at -43.82%. Stock’s beta reads 1.37. Stock has a price to book (P/B) ratio of 0.89 while price to sale or P/S ratio amounts to 749.08. Its return on asset (ROA) is -40.10% on average.
